首页 | 本学科首页   官方微博 | 高级检索  
检索        

糖尿病心肌后处理失保护机制及药物研究进展
引用本文:施思,刘慧敏,夏中元.糖尿病心肌后处理失保护机制及药物研究进展[J].海南医学,2016(11):1833-1836.
作者姓名:施思  刘慧敏  夏中元
作者单位:武汉大学人民医院麻醉科,湖北 武汉,430060
摘    要:糖尿病是以高血糖和内源性胰岛素产生或分泌不足为特点的代谢性疾病。糖尿病增加了急性心肌梗死等缺血性心脏病的发生率。心血管疾病的危险因素中,糖尿病可能降低心肌后处理中的心肌保护作用。目前,糖尿病心肌后处理中的影响机制仍不是十分清楚。因此,明确糖尿病心肌后处理中的作用机制,增强心肌对缺血再灌注损伤的耐受力,研究探索心肌保护的理想药物,具有非常重要的临床意义。本文就糖尿病心肌后处理失保护机制及药物研究进展等方面做一综述。

关 键 词:糖尿病  缺血-再灌注损伤  缺血后处理  药物后处理  心肌保护

Mechanism of losing protective effect of diabetes myocardical postconditioning and the progress of pharmacological research
Abstract:Diabetes is a metabolic disorder characterized by hyperglycemia due to insufficient insulin or its action on the body, which increases the incidence rates of ischemic heart disease including myocardial infraction. As an important risk factor of cardiovascular, it may attenuate the cardioprotection by postconditioning. The mechanism of interaction between diabetes and cardioprotective effect of IPostC is not completely understood yet. So, it has very important clinical significance to clearly define the mechanism of diabetic myocardial postconditioning, to enhance myocardial tolerance to ischemia-reperfusion injury and to explore the ideal drugs of myocardial protection. This arti-cle summarizes the relevant aspects of postconditioning associated with diabetes and the mechanism of myocardial protective drugs.
Keywords:Diabetes  Ischemic-reperfusion injury  Ischemic postconditioning  Pharmacological postcondition-ing  Myocardial protection
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号